Radical prostatectomy is a well-established treatment option in the management of localized and locally advanced prostate cancer. An extended lymphadenectomy is performed in case of substantial risk for lymph node involvement.
When biochemical recurrence (BCR) occurs, salvage radiotherapy (SRT) is performed. The benefit in terms of BCR-free survival (FS) and metastasis-FS by adding 6 months of androgen deprivation therapy (ADT) compared with SRT only has already been established. Retrospective evidence suggests that a longer schedule of ADT may be more beneficial compared with 6 months. This multicenter open-label randomized trial will include patients who need SRT after experiencing BCR post-radical prostatectomy with lymphadenectomy and pN0-status. Patients will be randomized for ADT duration (6 vs 24 months). Primary end point is distant metastasis-FS. Clinical Trial Registration: NCT04242017 (ClinicalTrials.gov).
Future oncology (London, England). 2020 Jul 15 [Epub ahead of print]
Charlien Berghen, Steven Joniau, Annouschka Laenen, Gaetan Devos, Kato Rans, Karolien Goffin, Karin Haustermans, Gert De Meerleer
Department of Radiation Oncology, KU Leuven, Leuven, Belgium., Department of Urology, KU Leuven, Leuven, Belgium., Department of Public Health & Primary Care, Interuniversity Institute for Biostatistics & Statistical Bioinformatics, KU Leuven, Leuven, Belgium., Department of Nuclear Medicine, KU Leuven, Leuven, Belgium.